

GLP-2(rat) (Ala-¹³C₃, ¹⁵N) (TFA)

Cat. No.:	HY-P1142S1
Molecular Formula:	C ₁₆₃ ¹³ C ₃ H ₂₅₆ N ₄₃ ¹⁵ NO ₅₆ S.xC ₂ HF ₃ O ₂
Sequence:	His-{Ala-13C3,15N}-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Thr-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp
Sequence Shortening:	H-{Ala-13C3,15N}-DGSFSDEMNTILDNLATRDFINWLIQTKITD <small>H-(Ala-¹³C₃, ¹⁵N)-DGSFSDEMNTILDNLATRDFINWLIQTKITD (TFA salt)</small>
Target:	Isotope-Labeled Compounds
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	GLP-2(rat) (Ala- ¹³ C ₃ , ¹⁵ N) TFA is ¹³ C and ¹⁵ N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Avik K, et, al. Is OM-3 synergistic with GLP-2 in intestinal failure. J Surg Res. 2017 Jan; 207: 7-12.
- [2]. Flavio GR, et, al. Glucagon-like peptide-2: divergent signaling pathways. J Surg Res. 2004 Sep; 121(1): 5-12.
- [3]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA